Grupo Asociado de Medicina Preventiva-Salud Pública y Atención Primaria

Resumen de actividad

Contribuir a la prestación de atención sanitaria personalizada mediante las estrategias propias de la Epidemiología y la Salud Pública. Sus actividades se orientan a la Epidemiología, la Protección y Promoción de la Salud, a la Prevención de la Enfermedad y la mejora de la salud individual y colectiva, la Seguridad del Paciente y la mejora de la Calidad Asistencial, la Docencia y la Investigación.

Contribuciones a la sociedad

El grupo de Medicina Preventiva-Salud Pública y Atención Primaria tiene un perfil claramente orientado a mejorar la atención a la sociedad, mediante la reducción de riesgos en la atención médica, la mejora en la utilización de los recursos y contribuir a realizar una atención basada en la evidencia. Todo ello con el fin último de proporcionar una mejor atención a los pacientes y a la comunidad.

Colaboraciones

NA

Tesis doctorales

76-GRÁFICO MED PREVENTIVA-tesis

Relación de publicaciones ordenadas por fecha de publicación

Vaccine certificates for international travelers in future pandemics.

Dal-Ré R, Becker SL, Launay O, Pavli A.

Eur J Clin Microbiol Infect Dis. Epub 2022 Dec 23. 2023 Feb.42(2):227-228.

PMID: 36562922

FI: 5,103

'Time out'-more transparency is required in 'Just-in-time' consent.

Dal-Ré R, Caplan AL, Voo TC.

Eur J Intern Med. 2022 Nov 29.

PMID: 36460540

FI: 7,749

Regulatory agencies disregard real-world effectiveness evidence on product labels beyond what is reasonable.

Dal-Ré R, Porcher R, Rosendaal FR, Schwarzer-Daum B.

J Clin Epidemiol. 2022 Nov 09.

PMID: 36371045

FI: 7,407

The approach to informed consent in acute care research.

Dal-Ré R, Caplan AL.

Lancet Respir Med. 2022 Nov 03.10(12):e107.

PMID: 36335957

FI: 102,642

Informed consent process in the I-SPY COVID trial is questionable.

Dal-Ré R, Caplan AL, Voo TC.

Eur J Intern Med. 2022 Oct 22.

PMID: 36283909

FI: 7,749

The Carlos III Research Institute and registration of clinical trials with non-regulated interventions.

Dal-Ré R.

Med Clin (Barc). 2022 Oct 14.

PMID: 36253204

FI: 3,2

COVID-19 drug research and the cohort multiple randomised controlled trial design.

Dal-Ré R.

Eur Respir J. 2022 Sep.60(3).

PMID: 35896204

FI: 33,801

Participants' informed consent in adaptive, platform drug trials in hospitalized COVID-19 patients: Not all approaches are ethically acceptable.

Dal-Ré R, Caplan AL, Voo TC.

Eur J Intern Med. 2022 09.103:1-3.

PMID: 35780073

FI: 7,749

The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans.

Dal-Ré R.

Therapie. 2022 Jul 13.

PMID: 35907680

FI: 3,367

High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries.

Dal-Ré R, Banzi R, Becker SL, Launay O, Pavli A.

Travel Med Infect Dis. 2022 Jul-Aug.48:102321.

PMID: 35390530

FI: 20,441

Ethical concern regarding the UK PANORAMIC COVID-19 trial.

Dal-Ré R, Holm S.

Br J Clin Pharmacol. 2022 Jul.88(7):3537-3538.

PMID: 35191085

FI: 3,716

Knowledge about COVID-19 and vaccine acceptability among priority groups defined for vaccination: a Cross-sectional study in Araba/Alava, Spain, before the vaccination against SARS-CoV-2.

Parraza-Diez N, Bermudez-Ampudia C, Cobos-Campos R, Garmendia I, Orruño E, Ojeda E, Garitano I, Robledo M, Portu J, Apiñaniz A.

Vaccine X. 2022 Jun 06:100176.

PMID: 35692459

FI: 0

Off-label prescription of BNT162b2 mRNA COVID-19 vaccine to <5-year-old children in the European Union.

Dal-Ré R, Calvo C, Neth O.

Acta Paediatr. 2022 Jun 03.

PMID: 35657672

FI: 4,056

Identification of seasonal variation in the diagnosis of acute myeloid leukaemia: a population-based study.

Sánchez-Vizcaíno F, Tamayo C, Ramos F, Láinez-González D, Serrano-López J, Barba R, Martin MD, Llamas P, Alonso-Dominguez JM.

Br J Haematol. 2022 May 31.

PMID: 35639095

FI: 8,615

Equipoise, standard of care and consent: responding to the authorisation of new COVID-19 treatments in randomised controlled trials.

Holm S, Lewis J, Dal-Ré R.

J Med Ethics. 2022 May 23.

PMID: 35606010

FI: 5,926

Heterologous COVID-19 Vaccination in Spain: A Case Study of Individual Autonomy in the Real World.

Dal-Ré R, Farré M, Lucena MI.

Value Health. 2022 05.25(5):770-772.

PMID: 35131144

FI: 5,156

Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach.

Dal-Ré R, Becker SL, Bottieau E, Holm S.

Lancet Infect Dis. 2022 Mar 29.

PMID: 35364019

FI: 71,421

The European Medicines Agency rejects the authorization of aducanumab for Alzheimer's disease.

Dal-Ré R.

Rev Neurol. 2022 03 16.74(6):207-208.

PMID: 35275397

FI: 1,235

Direct Medical Costs of Four Vaccine-Preventable Infectious Diseases in Older Adults in Spain.

Gil de Miguel Á, Eiros Bouza JM, Martínez Alcorta LI, Callejo D, Miñarro C, Vallejo-Aparicio LA, García A, Tafalla M, Cambronero MDR, Rodríguez R, Martin-Gomez L.

Pharmacoecon Open. 2022 Mar 07.

PMID: 35254649

FI: 0

August 2021 and the Delta variant: is mandatory vaccination of individuals against SARS-CoV-2 acceptable?

Dal-Ré R, Camps V.

Med Clin (Engl Ed). 2022 Mar 11.158(5):233-236.

PMID: 35165659

FI: 3,2

It is time to include real-world effectiveness data on medicinal product labels.

Dal-Ré R, Porcher R, Rosendaal FR, Schwarzer-Daum B.

Lancet Respir Med. 2022 03.10(3):e28-e29.

PMID: 35026176

FI: 102,642

Single research ethics committee review for multinational trials is a misconception.

Dal-Ré R.

J R Soc Med. 2022 Feb.115(2):46-47.

PMID: 35019796

FI: 18